Reducing length of stay with the direct oral anti-coagulants in low and intermediate risk pulmonary embolism: a single center experience
J Filopei, EE Bondarsky, M Ehrlich, M Islam… - Journal of Thrombosis …, 2020 - Springer
Direct oral anti-coagulants (DOACs) reduce hospital length-of-stay (LOS) in patients with
acute pulmonary embolism (PE) in clinical trials. There is a paucity of literature describing …
acute pulmonary embolism (PE) in clinical trials. There is a paucity of literature describing …
Early prescription of direct oral anticoagulant for the treatment of intermediate-high risk pulmonary embolism: a multi-center, observational cohort study
R Chopard, M Badoz, C Eveno, F Ecarnot, N Falvo… - Thrombosis …, 2020 - Elsevier
Objectives The safety and efficacy of direct oral anticoagulants (DOACs) in intermediate-
high risk pulmonary embolism (PE) are unknown. The aims of the present study were to …
high risk pulmonary embolism (PE) are unknown. The aims of the present study were to …
Retrospective analysis of direct-acting oral anticoagulants (DOACs) initiation timing and outcomes after thrombolysis in high-and intermediate-risk pulmonary …
A Wolfe, A Phillips, DM Tierney… - Clinical and Applied …, 2023 - journals.sagepub.com
Direct-acting oral anticoagulants (DOACs) are prescribed in the treatment of venous
thromboembolism, including pulmonary embolism (PE). Evidence is limited regarding the …
thromboembolism, including pulmonary embolism (PE). Evidence is limited regarding the …
Outpatient treatment in low-risk pulmonary embolism patients receiving direct acting oral anticoagulants is associated with cost savings
R Ghazvinian, J Elf, S Löfvendahl… - Clinical and Applied …, 2020 - journals.sagepub.com
Direct oral anticoagulants (DOAC) are first line treatment for pulmonary embolism (PE).
Treatment of acute PE is traditionally hospital based and associated with high costs. The …
Treatment of acute PE is traditionally hospital based and associated with high costs. The …
Non-recommended dosing of direct oral anticoagulants in the treatment of acute pulmonary embolism is related to an increased rate of adverse events
R Chopard, G Serzian, S Humbert, N Falvo… - Journal of Thrombosis …, 2018 - Springer
Dose adjustment of direct oral anticoagulants (DOACs) is not required in the setting of acute
PE treatment according to the manufacturer's labelling, beyond the contraindication in …
PE treatment according to the manufacturer's labelling, beyond the contraindication in …
Prescription patterns of direct oral anticoagulants in pulmonary embolism: A prospective multicenter French registry
R Chopard, JN Andarelli, S Humbert, N Falvo… - Thrombosis …, 2019 - Elsevier
Background Data regarding the use of direct oral anticoagulants (DOACs) for the treatment
of acute pulmonary embolism (PE) are sparse. We conducted a prospective multicentre …
of acute pulmonary embolism (PE) are sparse. We conducted a prospective multicentre …
Trends in length of hospital stay in acute pulmonary embolism over the years. What is changing in the era of direct oral anticoagulants?
L Masotti, V Vannucchi, M Poggi… - Journal of Cardiovascular …, 2017 - journals.lww.com
Letter to the Editor The optimal management of acute pulmonary embolism remains a
compelling challenge. In recent years, with the improvement of prognostic stratification, it …
compelling challenge. In recent years, with the improvement of prognostic stratification, it …
[HTML][HTML] Early, real-world experience with direct oral anticoagulants in the treatment of intermediate-high risk acute pulmonary embolism
SM Santos, S Cunha, R Baptista, S Monteiro… - Revista Portuguesa de …, 2017 - Elsevier
Introduction Intermediate-high risk pulmonary embolism (IHR-PE) has a poor prognosis, but
is under-represented in trials of direct oral anticoagulants (DOACs) in venous …
is under-represented in trials of direct oral anticoagulants (DOACs) in venous …
The effect of off-label use of reduced-dose direct oral anticoagulants therapy in the treatment of pulmonary embolism comparable to standard-dose therapy
S Yamazoe, H Imai, Y Ogawa, N Kano, Y Murase… - Heart and Vessels, 2024 - Springer
Direct oral anticoagulants (DOACs) have been shown to be effective and safe in preventing
pulmonary embolism recurrence. In this single-center retrospective observational study, we …
pulmonary embolism recurrence. In this single-center retrospective observational study, we …
Outpatient treatment of low‐risk pulmonary embolism in the era of direct oral anticoagulants: a systematic review
BC Maughan, L Frueh, MS McDonagh… - Academic …, 2021 - Wiley Online Library
Background Clinical guidelines have supported outpatient treatment of low‐risk pulmonary
embolism (PE) since 2014, but adoption of this practice has been slow. Direct oral …
embolism (PE) since 2014, but adoption of this practice has been slow. Direct oral …